2 completed, 1 terminated, 1 withdrawn. 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow Leidos Life Sciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vagal Approaches on Long COVID-19 Sonocea Sonic Augmentation Technology (SAT), Truvaga Electrical Vagus Nerve Stimulator - Long COVID Symptoms | Not applicable | Completed | Leidos Life Sciences | 546 | 2025-10-27 | 2026-01-07 |
| Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Withdrawn | Leidos Life Sciences | 2023-02-07 | 2023-10-10 | |
| Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Terminated | Leidos Life Sciences | 4 | 2021-12-29 | 2024-07-09 |
| LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Completed | Leidos Life Sciences | 4 | 2021-12-29 | 2025-12-16 |
COVID-19 (4) · Post-Acute COVID-19 Syndrome (1)
Celecoxib (3) · Famotidine (3)
United States (3)